Hemispherx Biopharma (HEB)
Hemispherx Biopharma Key Statistics
Pro Data ExportCurrent Valuation
Dividends and Shares
| Dividend | |
| Dividend Yield | 0.00% * |
| Cash Div. Payout Ratio TTM Pro | Go Pro |
| Payout Ratio TTM Pro | Go Pro |
| Dividend Date | |
| Ex-Dividend Date | |
| Last Split Factor | |
| Last Split Date |
Profitability
| Gross Profit Margin | -1058% |
| EBITDA Margin TTM Pro | Go Pro |
| Operating Margin TTM Pro | Go Pro |
| Profit Margin | -8197% |
Management Effectiveness
Liquidity and Solvency
| Altman Z-Score Pro | Go Pro |
| Current Ratio | 6.281 |
| Debt to Equity Ratio | 0.0469 |
| KZ Index Pro | Go Pro * |
| Tangible Common Equity Ratio Pro | Go Pro |
| Times Interest Earned TTM Pro | Go Pro |
Stock Price Performance
| Beta Pro | Go Pro |
| 1 Month Stock Returns | -17.40% |
| Year to Date Stock Returns | 43.52% |
| 1 Year Stock Returns | -40.43% |
| 3 Year Stock Returns | -83.43% |
| 52 Week High | 0.51 |
| 52 Week Low | 0.173 |
Income Statement
| Revenues TTM | 0.161M |
| Revenue Per Share TTM | 0.0012 |
| Revenue Growth | 40.74% |
| Gross Profit TTM | -0.879M |
| EBITDA TTM Pro | Go Pro |
| Income from Cont. Ops Pro | Go Pro |
| Net Income TTM | -9.015M |
| Earnings Per Share TTM | -0.07 |
| Other Comprehensive Income Pro | Go Pro |
Cash Flow Statement
| Cash Investing TTM | 8.65M |
| Cash Financing TTM | 1.62M |
| Cash Operations TTM | -10.09M |
| Capital Expenditures | 0.00 * |
Share Statistics
| Shares Outstanding | 135.83M * |
Balance Sheet
| Cash and ST Investments | 30.35M |
| Total Assets | 43.51M |
| Liabilities | 5.54M |
| Book Value | 37.96M |
| Book Value per Share | 0.28 |
| Tangible Book Value Pro | Go Pro |
| Tangible Book Value Per Share Pro | Go Pro |
| Long Term Debt | 0.00 * |
Earnings Quality
| Accruals Pro | Go Pro |
| Beneish M-Score Pro | Go Pro |
Key stats for HEB are based on the quarter ending Dec. 31, 2011. Asterisk (*) indicates value is based on preliminary data. Preliminary key stats for HEB are based on the quarter ending March 31, 2012. When preliminary data is not available for all parts of a calculation, we use non-preliminary data for all parts of that calculation.
You may also be interested in these HEB related companies
HEB News
$HEB maybe Carter can put Ampligen in e-cigarettes now that it's 2012 since he already explored putting it in real cigarettes in the 1980's
about 22 days ago by HankHill
about 22 days ago by HankHill
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2012
May 07, 4:35PM GlobeNewswire
May 07, 4:35PM GlobeNewswire
$heb ever hold a stock so you could laugh at it every day ? i have
about 40 days ago by roadkingtrdr
about 40 days ago by roadkingtrdr
Hemispherx Biopharma, Inc. to Host 2011 Year End Conference Call on Thursday, March 22, 2012
Mar 20, 8:30AM GlobeNewswire
Mar 20, 8:30AM GlobeNewswire
$HEB Cross over coming also a Triple top breakout at stockcharts.com on the P&F.
about 72 days ago by rtk
about 72 days ago by rtk
Hemispherx Publishes Data on the Bioactivity of Ampligen(R) in Chronic Fatigue Syndrome ("CFS")
Mar 19, 8:30AM GlobeNewswire
Mar 19, 8:30AM GlobeNewswire
$HEB , I am early but bot it this morning. loking for a nice pop
about 117 days ago by 3DTRADINGTRADER
about 117 days ago by 3DTRADINGTRADER
Hemispherx Biopharma Receives U.S. Patent Office Notification of Two New Patents Granted for Alferon(R) LDO
Jan 17, 8:30AM GlobeNewswire
Jan 17, 8:30AM GlobeNewswire
Hemispherx Biopharma (HEB) Recieves FDA Extension for NDA for Treatment of Chronic Fatigue Syndrome
Jan 11, 8:35AM Street Insider
Jan 11, 8:35AM Street Insider
$HEB shares up 14% following extension to modify NDA for treatment of CFS
about 140 days ago by Street_Insider
about 140 days ago by Street_Insider
Hemispherx Biopharma (HEB) Gets Extension from FDA for CFS NDA Modification
Jan 11, 8:31AM Street Insider
Jan 11, 8:31AM Street Insider
FDA Grants $HEB Extension in Its Pending New Drug Application for the Treatment of Chronic Fatigue
about 140 days ago by Benzinga
about 140 days ago by Benzinga
Hemispherx Biopharma Announces Further Adjournment on Proposal Number 4 From the 2011 Annual Meeting of Stockholders
Nov 09, 4:13PM GlobeNewswire
Nov 09, 4:13PM GlobeNewswire
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2011
Nov 09, 12:26PM GlobeNewswire
Nov 09, 12:26PM GlobeNewswire
Hemispherx Biopharma, Inc. to Host Conference Call on Chronic Fatigue Syndrome Progress Thursday, October 27, 2011
Oct 24, 10:22AM GlobeNewswire
Oct 24, 10:22AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HEB | 0.278 | +0.01 | +2.96% | 36.67M |
| HEAT | 4.04 | +0.00 | +0.00% | 15.59M |
| HE | 27.47 | +0.27 | +0.99% | 2.617B |
| HDY | 0.80 | -0.09 | -10.12% | 148.49M |
| HDSN | 3.96 | +0.11 | +2.86% | 91.55M |
| HDNG | 9.89 | +0.15 | +1.54% | 113.67M |
| HDG | 38.28 | +0.12 | +0.32% | |
| HDB | 29.36 | +0.76 | +2.66% | 22.18B |
| HD | 49.78 | +0.34 | +0.69% | 75.39B |
| HCSG | 19.97 | +0.24 | +1.24% | 1.319B |
